On September 30, 2024, bluebird bio, Inc. received a notice from Nasdaq's Listing Qualifications Department indicating that the company's stock had closed below the $1.00 minimum bid price requirement for 32 consecutive business days. This notice does not immediately affect the stock's listing on the Nasdaq Global Select Market, where it trades under the symbol 'BLUE'. The company has been granted a 180-day period, until March 31, 2025, to meet the minimum bid price requirement, which involves maintaining a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. If compliance is not achieved by the deadline, bluebird bio may be eligible for an additional 180-day period by transferring to the Nasdaq Capital Market, subject to certain conditions...Show More

On September 30, 2024, bluebird bio, Inc. received a notice from Nasdaq's Listing Qualifications Department indicating that the company's stock had closed below the $1.00 minimum bid price requirement for 32 consecutive business days. This notice does not immediately affect the stock's listing on the Nasdaq Global Select Market, where it trades under the symbol 'BLUE'. The company has been granted a 180-day period, until March 31, 2025, to meet the minimum bid price requirement, which involves maintaining a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. If compliance is not achieved by the deadline, bluebird bio may be eligible for an additional 180-day period by transferring to the Nasdaq Capital Market, subject to certain conditions. Failure to regain compliance within the allotted time frames could lead to delisting, which the company can appeal. bluebird bio is considering various options to regain compliance, including seeking shareholder approval for a reverse stock split at its 2024 Annual Meeting. However, there is no guarantee that the company will achieve compliance within the given period or maintain other Nasdaq listing requirements.